We can’t show the full text here under this license. Use the link below to read it at the source.
Regulating Tumor-Associated Macrophage Polarization by Cyclodextrin-Modified PLGA Nanoparticles Loaded with R848 for Treating Colon Cancer
Using Modified Nanoparticles Carrying R848 to Change Immune Cells in Tumors for Colon Cancer Treatment
AI simplified
Abstract
The average size of the CD@R848@NPs was 376 ± 30 nm with a surface charge of 21 ± 1 mV.
- The delivery system utilizes the targeting ability of to direct R848 to tumor-supporting M2-like macrophages.
- The combination of CD@R848@NPs with an anti-TNFR2 antibody may reduce the proportion of regulatory T cells (Tregs).
- CD@R848@NPs demonstrated increased penetration in tumor tissues compared to plain PLGA nanoparticles or R848.
- This formulation could dramatically reprogram M1-like macrophages and remove tumors.
- The new nanocapsule system is associated with prolonged survival in a colon adenocarcinoma model.
AI simplified
Key numbers
376 ± 30 nm
Average Size of Nanoparticles
Size of CD@R848@NPs measured in nanometers.
21 ± 1 mV
Surface Charge of Nanoparticles
Zeta potential of CD@R848@NPs measured in millivolts.
not specified
Prolonged Survival
Survival benefits observed in treated mice compared to control groups.